title: Adalimumab therapy for recalcitrant pyoderma gangrenosum.
abstract: OBJECTIVE
  To describe a patient with treatment-refractory pyoderma gangrenosum and the outcome of a novel therapeutic approach.
  
  
  METHODS
  Case report and review of the literature.
  
  
  RESULTS
  A patient with inflammatory bowel disease developed severe pyoderma gangrenosum while receiving treatment with the chimeric anti-TNF-alpha antibody infliximab. Despite subsequent trials of numerous immunosuppressive and immunomodulatory medications, the dermatologic disease progressed. The patient's ulcers finally resolved when treatment with adalimumab, a fully humanized monoclonal antibody specific for TNF-alpha, was initiated.
  
  
  CONCLUSIONS
  We report a novel application of the TNF-alpha inhibitor, adalimumab, in the treatment of pyoderma gangrenosum.
authors.affiliation: Department of Dermatology, Johns Hopkins Medical Institutions, Baltimore, MD, USA.
authors.forename: Margaret A
authors.initials: MA
authors.lastname: Fonder
authors.forename: Deborah L
authors.initials: DL
authors.lastname: Cummins
authors.forename: Benjamin D
authors.initials: BD
authors.lastname: Ehst
authors.forename: Grant J
authors.initials: GJ
authors.lastname: Anhalt
authors.forename: Jon H
authors.initials: JH
authors.lastname: Meyerle